Restructuring and Other Costs

6 Months Ended

Jul. 03, 2021

Restructuring and Related Activities [Abstract]

Restructuring and Other Costs, Net [Text Block]

Note 12.    Restructuring and Other Costs

In the first six months of 2021 the company recorded restructuring and other costs primarily associated with charges for impairment of acquired technology and third-party transaction/integration costs related to recent acquisitions, partially offset by credits for changes in estimates of contingent acquisition consideration. In the first six months of 2021, severance actions associated with facility consolidations and cost reduction measures affected less than 0.5% of the company’s workforce.

As of August 6, 2021, the company has identified restructuring actions that will result in additional charges of approximately $45 million, primarily in 2021, and expects to identify additional actions during 2021 which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred.

During the second quarter of 2021, the company recorded net restructuring and other costs (income) by segment as follows:

(In millions)	Cost of Revenues		Selling, General and Administrative Expenses		Restructuring and Other Costs		Total
Life Sciences Solutions	$	—	$	(57)	$	115	$	58
Specialty Diagnostics	—		—		3		3
Laboratory Products and Services	—		15		1		16
	$	—	$	(42)	$	119	$	77

During the first six months of 2021, the company recorded net restructuring and other costs (income) by segment as follows:

(In millions)	Cost of Revenues		Selling, General and Administrative Expenses		Restructuring and Other Costs		Total
Life Sciences Solutions	$	8	$	(47)	$	128	$	89
Analytical Instruments	—		—		3		3
Specialty Diagnostics	—		(2)		3		1
Laboratory Products and Services	—		23		(2)		21
Corporate	—		—		1		1
	$	8	$	(26)	$	133	$	115

The principal components of net restructuring and other costs (income) by segment are as follows:

Life Sciences Solutions

In the first six months of 2021, the Life Sciences Solutions segment recorded $128 million of restructuring and other costs, primarily charges of $110 million for impairment of acquired technology resulting from a reduction in expected cash flows, and compensation contractually due to employees of acquired businesses at the date of acquisition. The segment recorded $47 million of credits to selling, general, and administrative expense, principally credits for changes in estimates of contingent acquisition consideration, partially offset by third-party transaction costs related to recent acquisitions. The segment also recorded $8 million of charges to cost of revenues for the sale of inventories revalued at the date of acquisition.

Laboratory Products and Services

In the first six months of 2021, the Laboratory Products and Services segment recorded $21 million of net restructuring and other charges, primarily for third-party transaction/integration costs related to recent acquisitions.

The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.

(In millions)	Total (a)
Balance at December 31, 2020	21
Net restructuring charges incurred in 2021 (b)	12
Payments	(20)
Balance at July 3, 2021	$	13

(a)The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

(b)Excludes $121 million of net charges, principally for impairment of acquired technology and compensation contractually due and paid to employees of acquired businesses at the date of acquisition.

The company expects to pay accrued restructuring costs primarily through 2021.